



**Supplemental Figure 1. Increase in emetic symptoms evaluated by EORTC QLQ-C30 during the treatment is related to the use of opioids.** (A) Mean scores of nausea and vomiting symptoms evaluated by EORTC QLQ-C30 during the treatment in all-treated group. (B) Mean nausea and vomiting scores determined by EORTC QLQ-C30 according to the use of opioids analgesics (\*  $p < 0.05$  t test, \*\*  $p < 0.01$  t test). C) Prostate-loaded TAPCells immunotherapy did not affected other symptoms. Graphics represents mean scores of every symptoms during treatment protocol.



**Supplemental Figure 2. Global health status and functionality of treated patients were not affected by immunotherapy.** Graphics represents mean scores of global health status and functional subscales evaluated by EORTC QLQ-C30 questionnaire.



**Supplemental Figure 3. Proportion of central or effector Tm, as the expression of cytotoxic molecules, are not affected by TAPCells immunotherapy.** (A) PBMC obtained before first immunization and at DTH test were stained with specific monoclonal antibodies and analyzed by FACS, to determinate the proportion of effector Tm (Tem) and central Tm (Tcm). (B) PBMC obtained before first immunization and at DTH test were cultured overnight with autologous TAPCells loaded with prostate tumor lysate, stained with specific monoclonal antibodies and analyzed by FACS.